Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Omkar PharmachemBOM:532167 52 Interest Coverage is No Debt (1) as of Mar. 2026, which is 100% below its 10-year median of 8.00. GuruFocus rates BOM:532167 with a GF Score™ of 52/100 and a GF Value™ of ₹23.90 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 810 Business Services companies, Omkar Pharmachem ranks better than 76.17% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Omkar Pharmachem's
Operating Income
for the
three
months ended in Mar. 2026 was ₹0.17 Mil. Omkar Pharmachem's Interest Expense for the
three
months ended in Mar. 2026 was ₹0.00 Mil.
Omkar Pharmachem has no debt.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Omkar Pharmachem Ltd has no debt.
(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Omkar Pharmachem's Interest Coverage or its related term are showing as below:
BOM:532167'
s Interest Coverage Range Over the Past 10 Years
Min: 0.53 Med: 8 Max: 75.05
Current: 75.05
BOM:532167's Interest Coverage is ranked better than 76.17% of 810
companies
in the Business Services industry
Industry Median: 13.24
vs BOM:532167: 75.05
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Omkar Pharmachem Interest Coverage Related Terms
Omkar Pharmachem Interest Coverage Historical Data
* Premium members only.
The historical data trend for Omkar Pharmachem's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
BOM:532167 vs CTAS, CPRT, GPN: Interest Coverage Comparison
For the Specialty Business Services subindustry, Omkar Pharmachem's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Omkar Pharmachem Interest Coverage vs Business Services Industry
For the Business Services industry and Industrials sector, Omkar Pharmachem's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Omkar Pharmachem's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of No Debt <sup>(1)</sup> mean?
Omkar Pharmachem (BOM:532167) has a Interest Coverage of No Debt (1) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Omkar Pharmachem and its competitors. This is 88% below median its historical median of 8.00. Over the past decade, Omkar Pharmachem's Interest Coverage has ranged from 0.53 to 75.05. According to the industry distribution chart, Omkar Pharmachem ranks #193 out of 810 companies in the Business Services industry, placing it in the top 23.8%.
Is Omkar Pharmachem's Interest Coverage too high?
Omkar Pharmachem's current Interest Coverage of No Debt (1) is 88% below median its 10-year median of 8.00. Over the past 10 years, this metric has ranged from a low of 0.53 to a high of 75.05. Based on the distribution chart, Omkar Pharmachem ranks #193 out of 810 companies in the Business Services industry, which is in the top quartile — a strong position relative to peers. Overall, Omkar Pharmachem has a GF Score™ of 52/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Omkar Pharmachem's Interest Coverage compare to CTAS and CPRT?
According to the Business Services industry distribution chart, Omkar Pharmachem ranks #193 out of 810 companies for Interest Coverage. This places Omkar Pharmachem in the top 24% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 13.24. Historically, Omkar Pharmachem's own Interest Coverage has ranged from 0.53 to 75.05 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Business Services company?
The median Interest Coverage among Business Services companies is 13.24, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Omkar Pharmachem and its competitors. For the Business Services industry, the median Interest Coverage is 13.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Omkar Pharmachem's current Interest Coverage is No Debt (1), which is 88% below median its own 10-year median of 8.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omkar Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Omkar Pharmachem (BOM:532167) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹23.90, compared to a current price of ₹16.30 — trading 31.8% below its estimated fair value. The current Interest Coverage is No Debt (1), which is 88% below median its 10-year median of 8.00. Omkar Pharmachem's overall GF Score™ is 52/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Omkar Pharmachem (BOM:532167), the current Interest Coverage is No Debt (1) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Omkar Pharmachem (BOM:532167) Overvalued in 2026?
Based on GuruFocus' analysis, Omkar Pharmachem stock appears to be undervalued.
The current stock price of ₹16.30 is trading 31.8% below its estimated GF Value™ of ₹23.90.
GuruFocus considers Omkar Pharmachem to be Significantly Undervalued.
Key valuation signals for BOM:532167:
Interest Coverage: No Debt (1) (88% below median its 10-year median of 8.00)
GF Value™: ₹23.90 vs. price of ₹16.30 (31.8% below fair value)
No single metric tells the full story. See the BOM:532167 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532167 has been successfully added to your 
